Home » Stocks » GMTX

Gemini Therapeutics, Inc. (GMTX)

Stock Price: $10.35 USD -0.44 (-4.04%)
Updated May 11, 2021 9:45 AM EDT - Market open
Market Cap 508.24M
Revenue (ttm) n/a
Net Income (ttm) -40.84M
Shares Out 43.00M
EPS (ttm) -7.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $10.35
Previous Close $10.78
Change ($) -0.44
Change (%) -4.04%
Day's Open 10.38
Day's Range 10.26 - 10.56
Day's Volume 31,746
52-Week Range 9.80 - 19.09

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

1 week ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

1 week ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

4 weeks ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

4 weeks ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

2 months ago - Business Wire

SPACs dominated Wall Street in 2020. The backwards IPOs of these three companies suggests that 2021 will be more of the same.

Other stocks mentioned: APPH, HIMS
2 months ago - InvestorPlace

Gemini Therapeutics Inc (NASDAQ: GMTX) concludes enrollment in its Phase 2a ReGAtta study evaluating GEM103, a recombinant human complement factor H (CFH), in dry Age-related macular degeneration (AMD) ...

3 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

3 months ago - Business Wire

About GMTX

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Industry
Biotechnology
Founded
2015
Stock Exchange
NASDAQ
Ticker Symbol
GMTX
Full Company Profile

Financial Performance

Financial Statements